These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1715 related articles for article (PubMed ID: 25283629)

  • 1. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the clinical value of cancer stem cell markers in gliomas?
    Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
    Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Musashi-1 in gliomas.
    Dahlrot RH; Hansen S; Herrstedt J; Schrøder HD; Hjelmborg J; Kristensen BW
    J Neurooncol; 2013 Dec; 115(3):453-61. PubMed ID: 24057325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
    Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
    J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
    Wu B; Sun C; Feng F; Ge M; Xia L
    J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
    Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro neurosphere formation correlates with poor survival in glioma.
    C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S
    IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
    He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM
    Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and prognostic value of JAM-A in gliomas.
    Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
    J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival.
    Strojnik T; Røsland GV; Sakariassen PO; Kavalar R; Lah T
    Surg Neurol; 2007 Aug; 68(2):133-43; discussion 143-4. PubMed ID: 17537489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell markers in gliomas.
    Dell'Albani P
    Neurochem Res; 2008 Dec; 33(12):2407-15. PubMed ID: 18493853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
    Shin JH; Lee YS; Hong YK; Kang CS
    J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
    Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
    BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
    Li MW; Niu CS
    Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
    Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
    J Neurooncol; 2013 Sep; 114(3):309-17. PubMed ID: 23817809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
    Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
    Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
    Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
    Int J Clin Exp Pathol; 2013; 6(1):31-40. PubMed ID: 23236540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential expression of putative stem cell markers in gastric carcinogenesis.
    Wang T; Ong CW; Shi J; Srivastava S; Yan B; Cheng CL; Yong WP; Chan SL; Yeoh KG; Iacopetta B; Salto-Tellez M
    Br J Cancer; 2011 Aug; 105(5):658-65. PubMed ID: 21829201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.